BIIB Related Rumors
-
UPDATE: Bristol-Myers (BMY) Considered Deals for Biogen (BIIB), Shire (SHPG) - DJN
-
Elan Corp. (ELN) Active Following Large Block Trade; Traders Mull Market Chatter
-
Elan Corp (ELN) Has Mutlipe Items Driving Action Today
-
BioMarin (BMRN) Moves on Renewed Takeover Chatter
-
Elan Corp (ELN) Shares Fall Despite J&J (JNJ) Takeover Speculation
-
Baird Maintains Acorda Therapeutics (ACOR) Neutral Rating, Says Takeout Still Seems Best Option
-
Acorda (ACOR) Shares Surge as Biogen (BIIB) Exec Says Co. Looking at Acquisitions to Build MS Pipeline
-
Biotech Stocks Could See Action On Valeant (VRX) Bid for Cephalon (CEPH): (BIIB) (JAZZ) (DNDN) (REGN) (more...)
-
Wall Street Hubbub 7/26: A Genzyme (GENZ) Deal Coming, Is Biogen Idec (BIIB) Next, New BP CEO, Goldman Sachs the Movie
-
Genzyme (GENZ) Surges After Takeover Approach From Sanofi-Aventis
-
Biogen Idec (BIIB) Falls On Reports Sanofi Could Be After Genzyme
-
Wall Street Hubbub 7/21: Traders Nervous Ahead NFLX/BIDU Results, Dimon & Blankfein Not Welcome at FinReg Signing, Bernanke Set to Testify, BIIB/LLL/DTG In the Rumor Mill
-
Biogen Idec (BIIB) Sees Upside On Renewed Takeover Chatter
-
Genzyme (GENZ) Creeps Higher On Potential Biotech Mega-Deal
-
Allergan (AGN), Biogen Idec (BIIB) Higher As sanofi-aventis Prepares for Possible Mega-Deal
-
Reports Sanofi-aventis (SNY) Planning Large U.S. Acquisition
-
Biogen (BIIB) to Name George Scangos as New CEO -Reuters
-
Acorda (ACOR) Ticks Higher On New "Hold" Rating Which Discounts M&A Talk
-
'Takeover Fever' Continues In Biotech After Facet (FACT) Deal, Who's Next?
-
Biogen Idec (BIIB) Up On Renewed Takeover Speculation
-
Biotech Rumor Mill Hopping After Hostile Bid for OSI Pharmaceuticals (OSIP)
-
Merriman Curhan Pounds The Table On Facet Biotechnology (FACT) After Board Formally Rejects Biogen Offer
-
Facet Biotech (FACT) says received third-party interest after Biogen (BIIB) bid - Dow Jones
-
Biogen Idec (BIIB) Up On Resurfaced Takeover Chatter
-
Report J&J's Deal With Elan Could Turn Its Attention Toward Biogen (BIIB)
-
Sanofi-Aventis (SNY) On the Prowl For A Mega-Deal In the U.S.?
-
Icahn Says Future Is Big Pharma Will Buy Biotech (BIIB, AMLN)
-
Biogen Idec (BIIB) Shareholder Meeting In Recess, Icahn Wants Vote Closed
-
Biogen Idec (BIIB) Rises On Renewed Takeover Talk
-
Biogen (BIIB) In Talks to Buy Acorda (ACOR) -Bloomberg
-
Crucell NV (CRXL) Ticks Higher On Sanofi-Aventis (SNY) Takeover Speculation
-
Baird Downgrades Biogen Idec (BIIB) On Tysabri, Not Buying Takeover Talk
-
Reports Sanofi-Aventis (SNY) On The Prowl For Mergers
-
Goldman Sachs Recommends Biogen Idec (BIIB) Calls, Says Co A Takeover Target - Bloomberg
-
Baird Said Buy Biogen Idec (BIIB) On Any PFE/WYE Merger Talk Weakness
-
Biotech Takeover Buzz Hot and Heavy After ImClone Offer (ONXX, OSIP, BIIB, AMLN, XPNT, CYPB, ISPH)
-
Amylin Pharmaceuticals (AMLN) Could Be One To Watch On ImClone Bid
-
Biogen Idec (BIIB) Could Be One To Watch On ImClone Bid
-
Deutsche Bank Starts Biogen-IDEC (BIIB) at Hold
-
Reports Icahn Offered To Acquire Biogen Idec (BIIB) For As Much as $82/Share in Fall 2007
-
Icahn Confirmed Plans To Nominate 3 To Biogen (BIIB) Board, Says Buyout Process Was Flawed; Boosts Stake
-
What's A Fair Price for Biogen Idec (BIIB) To Trade At?
-
Icahn Capital Management shows a new 1.5 million share stake in Genzyme (GENZ)
-
Reports Glaxosmithkline's CEO No Comment on Biogen Idec (BIIB) Interest
-
Analyst Sees Biogen and ImClone as Likely M&A Targets and To a Lesser Extent Genzyme
-
Neurochem (NRMX) Higher on Takeover Rumors, Analyst Laughs At The Idea
-
Piper Jaffray & Co. Downgrades Biogen Idec (BIIB) to Underperform
-
What's Next For Icahn Following His BEAS and BIIB Windfall?
-
Could Icahn Target Biogen Idec (BIIB) Next?
-
StreetInsider.com Market Rumors 10/02
Back to BIIB Stock Lookup
